Refining Lung Cancer Screening Criteria in the Era of Value-Based Medicine

English version České info

In a Perspective on the Research Article by ten Haaf and colleagues, Steven Shapiro discusses the challenges of identifying screening strategies that maximize the number of cancers diagnosed, while minimizing the harms of overdiagnosis and maintaining cost-effectiveness.

Vyšlo v časopise: Refining Lung Cancer Screening Criteria in the Era of Value-Based Medicine. PLoS Med 14(2): e32767. doi:10.1371/journal.pmed.1002226
Kategorie: Perspective
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002226

Souhrn

Zdroje

1. Hashim D, Boffetta P, LaVecchia C, Rota M, Bertuccio P, Mavezzi M, et al. The global decrease in cancer mortality: trends and disparities. Annals of Oncol. 2016;27:926–933.

2. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced Lung- Cancer Mortality with Low-Dose Computed Tomographic Screening. New England Journal of Medicine. 2011;365(5):395–409. doi: 10.1056/NEJMoa1102873 21714641

3. ten Haaf K, Tammemagi MC, Bondy SJ, ver Aalst CM, Gu S, McGregor SE, et al. B. Performance and cost-effectiveness of computed tomography lung cancer screening scenarios in a population-based setting: a microsimulation modelling analysis in Ontario, Canada. PLoS Medicine. 2017;14(2): e1002225. doi: 10.1371/journal.pmed.1002225

4. U. S. Preventive services task force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement Ann of Intern Med. 2009; 151: 716–726.

5. Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YC, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015; 314: 1599–1614. doi: 10.1001/jama.2015.12783 26501536

6. Shapiro SD. The promise of precision medicine for health systems. Am J Health Syst Pharm. 2016; 73(23):1907–1908. doi: 10.2146/ajhp160681 27784661